{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:32:39Z","timestamp":1707525159563},"reference-count":50,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,24]]},"DOI":"10.7759\/cureus.42367","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T12:40:31Z","timestamp":1690202431000},"source":"Crossref","is-referenced-by-count":0,"title":["A Systematic Review of the Emerging Treatment for Hepatorenal Syndrome With a Principal Focus on Terlipressin: A Recent FDA-Approved Drug"],"prefix":"10.7759","author":[{"given":"Santhosh Raja","family":"Thangaraj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirra","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadia","family":"Arzoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siji  S","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008070669","article-title":"Creatinine kinetics and the definition of acute kidney injury","volume":"20","author":"Waikar SS","year":"2009","unstructured":"Waikar SS, Bonventre JV. Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol. 2009, 20:672-9. 10.1681\/ASN.2008070669","journal-title":"J Am Soc Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.05.041","article-title":"New developments in hepatorenal syndrome","volume":"16","author":"Mindikoglu AL","year":"2018","unstructured":"Mindikoglu AL, Pappas SC. New developments in hepatorenal syndrome. Clin Gastroenterol Hepatol. 2018, 16:162-177.e1. 10.1016\/j.cgh.2017.05.041","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000005595","article-title":"The comparative effectiveness of vasoactive treatments for hepatorenal syndrome: a systematic review and network meta-analysis","volume":"50","author":"Pitre T","year":"2022","unstructured":"Pitre T, Kiflen M, Helmeczi W, et al.. The comparative effectiveness of vasoactive treatments for hepatorenal syndrome: a systematic review and network meta-analysis. Crit Care Med. 2022, 50:1419-29. 10.1097\/CCM.0000000000005595","journal-title":"Crit Care Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010431","article-title":"Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis","volume":"97","author":"Wang H","year":"2018","unstructured":"Wang H, Liu A, Bo W, Feng X, Hu Y. Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2018, 97:e0431. 10.1097\/MD.0000000000010431","journal-title":"Medicine (Baltimore)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/207012","article-title":"Hepatorenal syndrome: aetiology, diagnosis, and treatment","volume":"2015","author":"Low G","year":"2015","unstructured":"Low G, Alexander GJ, Lomas DJ. Hepatorenal syndrome: aetiology, diagnosis, and treatment. Gastroenterol Res Pract. 2015, 2015:207012. 10.1155\/2015\/207012","journal-title":"Gastroenterol Res Pract"},{"key":"ref6","unstructured":"Medscape. Hepatorenal syndrome. (2022). Accessed: October 2022: https:\/\/emedicine.medscape.com\/article\/178208-overview."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1","volume":"150","author":"Boyer TD","year":"2016","unstructured":"Boyer TD, Sanyal AJ, Wong F, et al.. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016, 150:1579-1589.e2. 10.1053\/j.gastro.2016.02.026","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","article-title":"Terlipressin versus other vasoactive drugs for hepatorenal syndrome","volume":"27","author":"Israelsen M","year":"2017","unstructured":"Israelsen M, Krag A, Allegretti AS, Jovani M, Goldin AH, Winter RW, Gluud LL. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev. 2017, 27:011532. 10.1002\/14651858","journal-title":"Cochrane Database Syst Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01340406","article-title":"Hepatorenal syndrome: pathophysiology and management","volume":"1","author":"Wadei HM","year":"2006","unstructured":"Wadei HM, Mai ML, Ahsan N, Gonwa TA. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol. 2006, 1:1066-79. 10.2215\/CJN.01340406","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308874","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites","volume":"64","author":"Angeli P","year":"2015","unstructured":"Angeli P, Gines P, Wong F, et al.. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015, 64:531-7. 10.1136\/gutjnl-2014-308874","journal-title":"Gut"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S205328","article-title":"Hepatorenal syndrome type 1: Current challenges and future prospects","volume":"15","author":"Facciorusso A","year":"2019","unstructured":"Facciorusso A. Hepatorenal syndrome type 1: Current challenges and future prospects. Ther Clin Risk Manag. 2019, 15:1383-91. 10.2147\/TCRM.S205328","journal-title":"Ther Clin Risk Manag"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2687","article-title":"Hepatorenal syndrome: pathophysiology, diagnosis, and management","volume":"370","author":"Simonetto DA","year":"2020","unstructured":"Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020, 370:m2687. 10.1136\/bmj.m2687","journal-title":"BMJ"},{"key":"ref13","article-title":"Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1: A prospective, randomized trial","volume":"64","author":"Goyal O","year":"2016","unstructured":"Goyal O, Sidhu SS, Sehgal N, Puri S. Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1: A prospective, randomized trial. J Assoc Physicians India. 2016, 64:30-5.","journal-title":"J Assoc Physicians India"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.04.020","article-title":"Management of hepatorenal syndrome in the era of acute-on-chronic liver failure: Terlipressin and beyond","volume":"150","author":"Gin\u00e8s P","year":"2016","unstructured":"Gin\u00e8s P. Management of hepatorenal syndrome in the era of acute-on-chronic liver failure: Terlipressin and beyond. Gastroenterology. 2016, 150:1525-7. 10.1053\/j.gastro.2016.04.020","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i42.5552","article-title":"Acute renal dysfunction in liver diseases","volume":"13","author":"Betrosian AP","year":"2007","unstructured":"Betrosian AP, Agarwal B, Douzinas EE. Acute renal dysfunction in liver diseases. World J Gastroenterol. 2007, 13:5552-9. 10.3748\/wjg.v13.i42.5552","journal-title":"World J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i28.3684","article-title":"Acute kidney injury spectrum in patients with chronic liver disease: Where do we stand?","volume":"25","author":"Chancharoenthana W","year":"2019","unstructured":"Chancharoenthana W, Leelahavanichkul A. Acute kidney injury spectrum in patients with chronic liver disease: Where do we stand?. World J Gastroenterol. 2019, 25:3684-703. 10.3748\/wjg.v25.i28.3684","journal-title":"World J Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.2004.03877.x","article-title":"Vasopressin and terlipressin: pharmacology and its clinical relevance","volume":"59","author":"Kam PC","year":"2004","unstructured":"Kam PC, Williams S, Yoong FF. Vasopressin and terlipressin: pharmacology and its clinical relevance. Anaesthesia. 2004, 59:993-1001. 10.1111\/j.1365-2044.2004.03877.x","journal-title":"Anaesthesia"},{"key":"ref18","unstructured":"NEJM Journal Watch. Which vasoactive medications are most effective for hepatorenal syndrome?. (2022). Accessed: October 21, 2022: https:\/\/www.jwatch.org\/na55305\/2022\/10\/06\/which-vasoactive-medications-are-most-effective."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06710521","article-title":"Terlipressin: Hopes fulfilled or dashed?","volume":"17","author":"Pichler RH","year":"2022","unstructured":"Pichler RH, Swenson ER, Leary PJ, Paine CH. Terlipressin: Hopes fulfilled or dashed?. Clin J Am Soc Nephrol. 2022, 17:140-2. 10.2215\/CJN.06710521","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2022.07.108","article-title":"Noradrenaline versus terlipressin in the treatment of hepato-renal syndrome: A randomized study","volume":"12","author":"Koneti A","year":"2022","unstructured":"Koneti A, Singh M, Mallick S, et al.. Noradrenaline versus terlipressin in the treatment of hepato-renal syndrome: A randomized study. J Clin Exp Hepatol. 2022, 12:10. 10.1016\/j.jceh.2022.07.108","journal-title":"J Clin Exp Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.53350\/pjmhs22167332","article-title":"Hepatorenal syndrome: examine the treatment effectiveness of terlipressin and albumin","volume":"7","author":"Khan ZA","year":"2022","unstructured":"Khan ZA, Shahzad M, Iqbal J, Aslam MI, Yar AA, Javed M. Hepatorenal syndrome: examine the treatment effectiveness of terlipressin and albumin. Pak. J. Med. Health Sci. 2022, 7:332-333. 10.53350\/pjmhs22167332","journal-title":"Pak. J. Med. Health Sci"},{"key":"ref22","article-title":"A comparative assessment of norepinephrine and terlipressin in the management of hepatorenal syndrome","volume":"14(1)","author":"Jha UC","year":"2021","unstructured":"Jha UC, Das NL, Kumar B. A comparative assessment of norepinephrine and terlipressin in the management of hepatorenal syndrome. Int J Pharm Clin Res. 2021, 14(1):122-127.","journal-title":"Int J Pharm Clin Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008290","article-title":"Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome","volume":"384","author":"Wong F","year":"2021","unstructured":"Wong F, Pappas SC, Curry MP, et al.. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021, 384:818-28. 10.1056\/NEJMoa2008290","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12600","article-title":"Terlipressin effect on hepatorenal syndrome: Updated meta-analysis of randomized controlled trials","volume":"5","author":"Mohamed MM","year":"2021","unstructured":"Mohamed MM, Rauf A, Adam A, Kheiri B, Lacasse A, El-Halawany H. Terlipressin effect on hepatorenal syndrome: Updated meta-analysis of randomized controlled trials. JGH Open. 2021, 5:896-901. 10.1002\/jgh3.12600","journal-title":"JGH Open"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/2050640619825719","article-title":"Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2","volume":"7","author":"Nguyen-Tat M","year":"2019","unstructured":"Nguyen-Tat M, J\u00e4ger J, Rey JW, et al.. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2. United European Gastroenterol J. 2019, 7:529-37. 10.1177\/2050640619825719","journal-title":"United European Gastroenterol J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14052","article-title":"Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies","volume":"45","author":"Sanyal AJ","year":"2017","unstructured":"Sanyal AJ, Boyer TD, Frederick RT, et al.. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther. 2017, 45:1390-402. 10.1111\/apt.14052","journal-title":"Aliment Pharmacol Ther"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial","volume":"62","author":"Cavallin M","year":"2015","unstructured":"Cavallin M, Kamath PS, Merli M, et al.. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology. 2015, 62:567-74. 10.1002\/hep.27709","journal-title":"Hepatology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107466","article-title":"Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis","volume":"9","author":"Nassar Junior AP","year":"2014","unstructured":"Nassar Junior AP, Farias AQ, D' Albuquerque LA, Carrilho FJ, Malbouisson LM. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One. 2014, 9:e107466. 10.1371\/journal.pone.0107466","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.08.016","article-title":"Terlipressin and the treatment of hepatorenal syndrome: How the CONFIRM trial moves the story forward","volume":"79","author":"Belcher JM","year":"2022","unstructured":"Belcher JM, Parada XV, Simonetto DA, et al.. Terlipressin and the treatment of hepatorenal syndrome: How the CONFIRM trial moves the story forward. Am J Kidney Dis. 2022, 79:737-45. 10.1053\/j.ajkd.2021.08.016","journal-title":"Am J Kidney Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/lt.25834","article-title":"Role of terlipressin and albumin for hepatorenal syndrome in liver transplantation","volume":"26","author":"Sharma P","year":"2020","unstructured":"Sharma P, Moore K, Ganger D, Grewal P, Brown RS Jr. Role of terlipressin and albumin for hepatorenal syndrome in liver transplantation. Liver Transpl. 2020, 26:1328-36. 10.1002\/lt.25834","journal-title":"Liver Transpl"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1564794","article-title":"Hepatorenal syndrome: A review of pathophysiology and current treatment options","volume":"32","author":"Erly B","year":"2015","unstructured":"Erly B, Carey WD, Kapoor B, McKinney JM, Tam M, Wang W. Hepatorenal syndrome: A review of pathophysiology and current treatment options. Semin Intervent Radiol. 2015, 32:445-54. 10.1055\/s-0035-1564794","journal-title":"Semin Intervent Radiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2013.12.001","article-title":"Pathophysiology of portal hypertension","volume":"18","author":"Iwakiri Y","year":"2014","unstructured":"Iwakiri Y. Pathophysiology of portal hypertension. Clin Liver Dis. 2014, 18:281-91. 10.1016\/j.cld.2013.12.001","journal-title":"Clin Liver Dis"},{"key":"ref34","unstructured":"emDocs. Hepatorenal syndrome: ED presentation, evaluation, and management. (2019). Accessed: October 17, 2022: http:\/\/www.emdocs.net\/hepatorenal-syndrome-ed-presentation-evaluation-and-management\/."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.15454","article-title":"The renin-angiotensin-aldosterone system and its suppression","volume":"33","author":"Ames MK","year":"2019","unstructured":"Ames MK, Atkins CE, Pitt B. The renin-angiotensin-aldosterone system and its suppression. J Vet Intern Med. 2019, 33:363-82. 10.1111\/jvim.15454","journal-title":"J Vet Intern Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510230122","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis","volume":"23","author":"Arroyo V","year":"1996","unstructured":"Arroyo V, Gin\u00e8s P, Gerbes AL, et al.. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996, 23:164-76. 10.1002\/hep.510230122","journal-title":"Hepatology"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.2.288","article-title":"Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study","volume":"47","author":"Brensing KA","year":"2000","unstructured":"Brensing KA, Textor J, Perz J, et al.. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000, 47:288-95. 10.1136\/gut.47.2.288","journal-title":"Gut"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14009","article-title":"Terlipressin: Current and emerging indications in chronic liver disease","volume":"33","author":"Papaluca T","year":"2018","unstructured":"Papaluca T, Gow P. Terlipressin: Current and emerging indications in chronic liver disease. J Gastroenterol Hepatol. 2018, 33:591-8. 10.1111\/jgh.14009","journal-title":"J Gastroenterol Hepatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.5527\/wjn.v4.i5.511","article-title":"Hepatorenal syndrome: Update on diagnosis and treatment","volume":"4","author":"Baraldi O","year":"2015","unstructured":"Baraldi O, Valentini C, Donati G, et al.. Hepatorenal syndrome: Update on diagnosis and treatment. World J Nephrol. 2015, 4:511-20. 10.5527\/wjn.v4.i5.511","journal-title":"World J Nephrol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/cld.209","article-title":"Current treatment strategies for hepatorenal syndrome","volume":"2","author":"Sol\u00e0 E","year":"2013","unstructured":"Sol\u00e0 E, Guevara M, Gin\u00e8s P. Current treatment strategies for hepatorenal syndrome. Clin Liver Dis (Hoboken). 2013, 2:136-9. 10.1002\/cld.209","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000537","article-title":"Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation","volume":"28","author":"Mattos \u00c2Z","year":"2016","unstructured":"Mattos \u00c2Z, Mattos AA, Ribeiro RA. Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation. Eur J Gastroenterol Hepatol. 2016, 28:345-51. 10.1097\/MEG.0000000000000537","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20262","article-title":"Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome","volume":"40","author":"Wong F","year":"2004","unstructured":"Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004, 40:55-64. 10.1002\/hep.20262","journal-title":"Hepatology"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.5527\/wjn.v4.i2.277","article-title":"Management of hepatorenal syndrome","volume":"4","author":"Dundar HZ","year":"2015","unstructured":"Dundar HZ, Y\u0131lmazlar T. Management of hepatorenal syndrome. World J Nephrol. 2015, 4:277-86. 10.5527\/wjn.v4.i2.277","journal-title":"World J Nephrol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221102679","article-title":"Management of hepatorenal syndrome in liver cirrhosis: a recent update","volume":"15","author":"Bera C","year":"2022","unstructured":"Bera C, Wong F. Management of hepatorenal syndrome in liver cirrhosis: a recent update. Therap Adv Gastroenterol. 2022, 15:17562848221102679. 10.1177\/17562848221102679","journal-title":"Therap Adv Gastroenterol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.05873.x","article-title":"Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis","volume":"24","author":"Narahara Y","year":"2009","unstructured":"Narahara Y, Kanazawa H, Taki Y, et al.. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. J Gastroenterol Hepatol. 2009, 24:1791-7. 10.1111\/j.1440-1746.2009.05873.x","journal-title":"J Gastroenterol Hepatol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.675948","article-title":"Norepinephrine is more effective than midodrine\/octreotide in patients with hepatorenal syndrome-acute kidney injury: A randomized controlled trial","volume":"12","author":"El-Desoki Mahmoud EI","year":"2021","unstructured":"El-Desoki Mahmoud EI, Abdelaziz DH, Abd-Elsalam S, Mansour NO. Norepinephrine is more effective than midodrine\/octreotide in patients with hepatorenal syndrome-acute kidney injury: A randomized controlled trial. Front Pharmacol. 2021, 12:675948. 10.3389\/fphar.2021.675948","journal-title":"Front Pharmacol"},{"key":"ref47","article-title":"Norepinephrine versus terlipressin in patients with type 1 hepatorenal syndrome refractory to treatment with octreotide, midodrine, and albumin (a prospective randomized compar- ative study)","volume":"7","author":"Badawy S","year":"2013","unstructured":"Badawy S, Meckawy N, Ahmed A. Norepinephrine versus terlipressin in patients with type 1 hepatorenal syndrome refractory to treatment with octreotide, midodrine, and albumin (a prospective randomized compar- ative study). Egyptian J Cardiothorac Anesth. 2013, 7:13-18.","journal-title":"Egyptian J Cardiothorac Anesth"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12179","article-title":"Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study","volume":"33","author":"Ghosh S","year":"2013","unstructured":"Ghosh S, Choudhary NS, Sharma AK, et al.. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int. 2013, 33:1187-93. 10.1111\/liv.12179","journal-title":"Liver Int"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study","volume":"47","author":"Alessandria C","year":"2007","unstructured":"Alessandria C, Ottobrelli A, Debernardi-Venon W, et al.. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007, 47:499-505. 10.1016\/j.jhep.2007.04.010","journal-title":"J Hepatol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1097\/01.NAJ.0000919728.07518.8e","article-title":"First drug for treating hepatorenal syndrome","volume":"123","author":"Aschenbrenner DS","year":"2023","unstructured":"Aschenbrenner DS. First drug for treating hepatorenal syndrome. Am J Nurs. 2023, 123:27. 10.1097\/01.NAJ.0000919728.07518.8e","journal-title":"Am J Nurs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/169362-a-systematic-review-of-the-emerging-treatment-for-hepatorenal-syndrome-with-a-principal-focus-on-terlipressin-a-recent-fda-approved-drug","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:53Z","timestamp":1707508913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/169362-a-systematic-review-of-the-emerging-treatment-for-hepatorenal-syndrome-with-a-principal-focus-on-terlipressin-a-recent-fda-approved-drug"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":50,"URL":"https:\/\/doi.org\/10.7759\/cureus.42367","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,24]]}}}